americanpharmaceuticalreviewAugust 28, 2017
Tag: Johnson & Johnson , PTG-200 , IBD
Protagonist Therapeutics has closed the worldwide license and collaboration transaction for PTG-200 with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, following termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following closure of the transaction, Protagonist received the upfront payment of $50 million originally announced by the two companies as part of the agreement on May 30, 2017.
The agreement provides Janssen Biotech with a worldwide license for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist for all indications including inflammatory bowel disease (IBD). PTG-200 is expected to enter Phase 1 clinical testing before the end of 2017.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: